Jeff McKenna

Jeff McKenna

Company: Novartis AG

Job title: Director


Redefining the Druggable Proteome with Covalency Enabled Drug Discovery 9:30 am

Creating and identifying novel chemical probes to interrogate novel biology through the use of chemoproteomic platforms Discussing novel modalities shown to be accessible using covalent LMW ligands Elucidating the Novartis-Berkeley collaboration, its scope and learnings, to advance covalent drug discoveryRead more

day: Conference Day One

Panel Discussion: How Can We Build Covalent Chemistries that Drive Selectivity & Open New Unvalidated Target Spaces such as Non-Cysteine Residues 11:15 am

What are some example novel warheads that are being explored to advance covalent modification to new acid residues? How can we effectively target “soft” nucleophiles that are not as reactive as cysteine? Are there unvalidated target spaces that have not yet been drugged which covalency can open up? Such as through nonsmall molecule drugs or…Read more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.